glp-1 nhs Is Health Improvement Fund's oral solution effective for PCOS symptoms? Women and the middle classes

Description

Approved by the Central Drugs Standard Control Organization (CDSCO), Mounjaro is the first dual-target therapy that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors, helping regulate blood sugar levels while promoting weight loss

It reduces hunger by stimulating the brain's appetite center

Months 4 through 6 on tirzepatide: Weeks 1 to 4 back at 2.5 mg, the lowest starting dose

Every meal is portioned correctly and macro-balanced to support muscle preservation

Second-generation oral semaglutide, whose bioavailability and safety have been significantly improved by the application of new excipients and formulation optimization, but its gastrointestinal side effects are still obvious (Nielsen et al., 2025)